FDA Approval this Month (Mcap 33 M) Shares Out 6 M

[Biotechmaster]

This unknown gem is awaiting FDA approval and Major Phase II Results for their Flagship product DSC127 in 1Q 2011 .The real Value is between 20- 30$ per Share !!

ITS A WIN WIN SITUATION FROM THIS LEVEL .DO YOUR RESEARCH AND REALISE THE MEGA POTENTIAL !GL



Derma Science (DSCI)

Market Cap : 30.5 M
Share Price : 4.65

Annual Revenue : 55 M


SHARE STATISTIC :

Shares Out : 6.5 M
Float: 3.2 M
Held by Insiders : 3 M



ENOUGH CASH :

As of September 30, 2010, working capital was $9,587,806, and cash and cash equivalents were $409,505. Line of credit borrowing was $3,658,625 at quarter end with approximately $1,200,000 of additional availability.



TWO APPROVALS ON THE WAY (See Slide presentation below for more Infos) :

We made progress with our two 510(k) submissions to the U.S. Food and Drug Administration for new MEDIHONEY line extensions and are looking forward to bringing those products to market in the near future.



PHASE II RESULTS FOR MAJOR DRUG THIS MONTH :

"We were very pleased to complete patient enrollment at the end of September in our Phase II trial with DSC127 in diabetic wound healing. We anticipate reporting top-line efficacy data between late December and mid January. Should the trial be successful, we are evaluating several options, including bringing on a partner.


Check out this Slide Presentation :

[Biotechmaster]

The interest in DSCI has just begun .Nice Volume yesterday it was the highest since feb 2010 . 63000shares of the Volume was a Buy .

Good News coming in the next few days better load up before the stock explodes . Buy with both hands at current level .




Upcoming Milestones



Expect FDA 510k Clearance for Medihoney gel 4Q10 = ANY TIME NOW


Derma Sciences expects to announce top-line efficacy results of its Phase 2 clinical study with DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction, by the end of January 2011.

[Biotechmaster]

Great Article out ...This unknown gem is still wayyyy Undervalued .Market Cap of $ 45 M is a big joke for this great Company .




What's Making News At Derma Sciences?
1/26/2011 5:47 AM ET

(RTTNews) - Shares of Derma Sciences Inc. (DSCI: News ), a medical device / pharmaceutical company focused on wound care, have gained over 50 percent in the last five days as investors eye a couple of near-term catalysts.

The company is developing a drug for wound healing and scar reduction - DSC127, which is under a phase II study on diabetic foot ulcer healing. The phase 1 trial with DSC127 was successfully completed in 2007, and the initial key efficacy results from the phase II trial are expected by the end of this month.

In animal studies, DSC127 has shown to be significantly more effective than Johnson & Johnson's Regranex, the only FDA-approved drug for wound healing.

The total market for accelerated healing and scar reduction drug is estimated at $30 billion and DSC127 has blockbuster potential, according to Derma Sciences. Regranex, which bears a black box warning as it is linked to an increased risk of cancer death, has annual sales of $100 million.

The company will be evaluating future development and partnering opportunities for DSC127 after reporting the top line phase II results. Derma Sciences was also awarded $244,479 from the U.S. government under the Patient Protection and Affordable Care Act related to the development of DSC127.

Derma Sciences, which is focused on wound care products, has three primary business segments - Advanced Wound Care, Basic Wound Care and Drug Development.

The Advanced Wound Care segment includes proprietary dressings like MEDIHONEY, BIOGUARD, XTRASORB, MedEfficiency and ALGICELL. This is a high-growth, high-margins segment. Last July, the company submitted a 510(k) application to the FDA for MEDIHONEY Gel wound & burn dressing and is awaiting the regulatory agency's decision.

The Basic Wound Care segment is the company's core business, generating over 80 percent of current total revenue. This segment includes both branded and private-label/OEM bandages, gauze-based dressings, wound closure strips, and first aid products.

For the nine months ended September 30, 2010 net sales were up 18 percent to $41.17 million. Net loss for the period widened to $1.97 million or $0.31 per share from $1.18 million or $0.23 per share in 2009. At September 30, 2010, the company had cash and cash equivalents of $409,505 compared to $243,524 in December 31, 2009.

DSCI underwent a 1-for-8 reverse split, which became effective on February 1, 2010. The stock, which has thus far hit a 52-week low of $0.73 and a 52-week high of $9.00, closed Tuesday's trading at $6.98, up 5.28 percent.